120例脑膜瘤病理表型与肿瘤分级及预后的相关性研究-东南大学学报医学版

120例脑膜瘤病理表型与肿瘤分级及预后的相关性研究

单位：1. 南方医科大学珠江医院神经外科, 广东广州 510282;
2. 广东神经外科研究所, 广东广州 510282

分类号：R741.02

出版年·卷·期（页码）：2016·35·第五期（688-691）

摘要：

目的：探讨脑膜瘤组织病理表型与其WHO分级及预后的相关性。方法：采用免疫组化检测120例脑膜瘤病理标本中Vimentin、EMA、S-100、GFAP、Ki67、P53的表达，分析以上分子与脑膜瘤WHO分级、术后复发的相关性。结果：（1）120例脑膜瘤中Vimentin均为阳性表达，EMA平均表达阳性率为90%，Vimentin和EMA表达在3组WHO分级脑膜瘤的组织中差异无统计学意义。（2）S-100平均表达阳性率为23%，在3组WHO分级的脑膜瘤中差异无统计学意义；GFAP平均表达阳性率为4%，在WHO Ⅱ级脑膜瘤中表达明显高于WHO Ⅰ级与WHO Ⅲ级。（3）Ki67和P53的平均阳性表达率为46%和32%，两者均随着脑膜瘤WHO级别升高而表达增高。（4）Ki67的表达与脑膜瘤的复发有相关性。结论：Vimentin和EMA的组织表达阳性可作为脑膜瘤的分子诊断特征；Ki67和P53与脑膜瘤恶性程度密切相关，可以作为良恶性鉴别的分子标志物；Ki67可作为脑膜瘤复发的预后指标之一。

Objective: To investigate the correlation of pathological phenotype and prognosis of meningioma with the WHO classification. Methods: The expressions of Vimentin, EMA, S-100, GFAP, Ki67 and P53 in 120 cases of meningioma pathological specimens were detected using immunohistochemical method, and the relevance between these molecular markers and WHO classification in meningioma and also its prognosis was analyzed. Results: (1) Of 120 cases of meningioma, Vimentin expression was all positive. EMA expression positive rate was 90% on average. There was no obvious difference between Vimentin and EMA expression among the three meningioma tissues of the WHO classification. (2) The average expression rate of S-100 was 23% and there was not obvious difference among the three groups. The average expression rate of GFAP was 4% and it was significantly higher expressed in WHO Ⅱ meningioma tissues than in WHO Ⅰand WHO Ⅲ meningioma tissues. (3) The average expression rate of Ki67 and P53 were 46% and 32%, both increasing along with the WHO degree. (4) The expression of Ki67 was associated with the recurrence of meningioma. Conclusion: The expression of Vimentin and EMA can be used as molecular markers of meningioma. The expression of Ki67 and P53 are closely related to WHO degree of meningioma and can be used as molecular markers identifying benign or malignancy meningioma. Ki67 can be used as a prognostic indicator for recurrent meningioma.

参考文献：

[1] 武忠弼.中华外科病理学[M].北京:人民卫生出版社,2006:2017-2024.
[2] KIEIHUES P,GAVENEE W K.WHO神经系统肿瘤病理学和遗传学[M].李青,徐庆中,主译.北京:人民卫生出版社,2006:206-217.
[3] 许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231.
[4] MALLOY K A,CHIGBU D I.Anterior temporal chordoid meningioma causing compressive optic neuropathy[J].Optom Vis Sci,2011,88(5):645-651.
[5] WEN M,JUNG S,MOON K S,et al.Immunohistochemical profile of the dural tail in intracranial meningiomas[J].Acta Neurochir(Wien),2014,156(12):2263-2273.
[6] BACKER-GRONDAHL T,MOEN B H,ARNLI M B,et al.Immunohistochemical characterization of brain-invasive meningiomas[J].Int J Clin Exp Pathol,2014,7(10):7206-7219.
[7] LYUBIMOVA N V,TOMS M G,FU R G,et al.Biochemical markers of brain tumours[J].Klin Lab Diagn,2013(10):71-72.
[8] EBERLIN L S,NORTON I,ORRINGER D,et al.Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors[J].Proc Natl Acad Sci U S A,2013,110(5):1611-1616.
[9] 张明杰,刁宏宇,王成林.影响胶质瘤复发时间的多因素分析[J].现代医学,2008,36(1):33-36.
[10] BABU S,UPPIN S G,UPPIN M S,et al.Meningiomas:correlation of Ki67 with histological grade[J].Neurol India,2011,59(2):204-207.
[11] SOGA T.Cancer metabolism:key players in metabolic reprogramming[J].Cancer Sci,2013,104(3):275-281.
[12] SUGHRUE M E,RUTKOWSKI M J,ARANDA D,et al.Factors affecting outcome following treatment of patients with cavernous sinus meningiomas[J].J Neurosurg,2010,113(5):1087-1092.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录